<!DOCTYPE html>
<html class="client-js"><head>
  <meta charset=UTF-8"UTF-8">
  <title>Lenalidomide</title>
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <script>
    function importScript() { return 1 } // this is to avoid the error from site.js
  </script>
  <link rel="canonical" href="https://en.wikipedia.org/wiki/Lenalidomide">
  <link href="../-/s/css_modules/ext.cite.ux-enhancements.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.ux-enhancements.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/ext.cite.styles.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/ext.cite.styles.css" rel="stylesheet" type="text/css" class="">
<link href="../-/s/css_modules/fi000001.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/skins.minerva.base.reset|skins.minerva.content.styles|ext.cite.style|site.styles|mobile.app.pagestyles.android|mediawiki.page.gallery.styles|mediawiki.skinning.content.parsoid.css" rel="stylesheet" type="text/css" class="">
  <link href="../-/s/css_modules/style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/style.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/content.parsoid.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/content.parsoid.css" rel="stylesheet" type="text/css" class=""><link href="../-/s/css_modules/inserted_style.css" tppabs="https://ptable.com/wiki/compounds/-/s/css_modules/inserted_style.css" rel="stylesheet" type="text/css" class="">
  <script src="../-/j/js_modules/script.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/script.js" class=""></script><script src="../-/j/js_modules/masonry.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/masonry.min.js" class=""></script><script src="../-/j/js_modules/article_list_home.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/article_list_home.js" class=""></script><script src="../-/j/js_modules/images_loaded.min.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/images_loaded.min.js" class=""></script><script src="../-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/node_module/details-element-polyfill/dist/details-element-polyfill.js" class=""></script>
<link type="root" href=""></head>

<body class="mediawiki mw-hide-empty-elt ns-0 ns-subject stable skin-minerva action-view animations">
  <div id="mw-mf-viewport" class="feature-header-v2">
    <div id="mw-mf-page-center">
      <div id="content" class="mw-body">
        <a id="top"></a>
        <div id="bodyContent" class="content mw-parser-output">
          
          <div id="mw-content-text" style="direction: ltr;"><h1 class="section-heading" tabindex="0" aria-haspopup="true" data-section-id="0">
  <span class="mw-headline" id="title_0">Lenalidomide</span>
</h1>
<div id="mf-section-0" class="mf-section-0" aria-pressed="true" aria-expanded="true">
  <p><b>Lenalidomide</b>, sold under the trade name <b>Revlimid</b> among others, is a medication used to treat multiple myeloma (MM) and myelodysplastic syndromes (MDS).<span class="mw-ref" id="cite_ref-AHFS2019_2-0"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> For MM it is used after at least one other treatment and generally together with <a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">dexamethasone</a>.<span class="mw-ref" id="cite_ref-AHFS2019_2-1"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is taken by mouth.<span class="mw-ref" id="cite_ref-AHFS2019_2-2"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p></p>
<table class="infobox" style="width:22em;border-spacing:2px;"><caption><span>Lenalidomide</span></caption><tbody><tr><td colspan="2" style="text-align:center"><figure-inline><img src="../I/m/Lenalidomide_enantiomers.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Lenalidomide_enantiomers.svg.png" data-file-width="512" data-file-height="634" data-file-type="drawing" height="248" width="200"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Clinical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pronunciation</th><td><span class="rt-commentedText nowrap"><span class="IPA nopopups noexcerpt">/<span style="border-bottom:1px dotted"><span>ˌ</span><span>l</span><span>ɛ</span><span>n</span><span>ə</span><span>ˈ</span><span>l</span><span>ɪ</span><span>d</span><span>oʊ</span><span>m</span><span>aɪ</span><span>d</span></span>/</span></span><span> </span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Trade names</th><td>Revlimid, Linamide, others</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">AHFS/Drugs.com</th><td><span><a href="javascript:if(confirm('https://www.drugs.com/monograph/lenalidomide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/lenalidomide.html'" tppabs="https://www.drugs.com/monograph/lenalidomide.html" class="external text external">Monograph</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">MedlinePlus</th><td><span><a href="javascript:if(confirm('https://medlineplus.gov/druginfo/meds/a608001.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://medlineplus.gov/druginfo/meds/a608001.html'" tppabs="https://medlineplus.gov/druginfo/meds/a608001.html" class="external text external">a608001</a></span></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">License data</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">EU</abbr></small><span>&nbsp;</span>EMA:<span>&nbsp;</span><span><a href="javascript:if(confirm('http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Lenalidomide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Lenalidomide'" tppabs="http://www.ema.europa.eu/ema/index.jsp?curl=%2Fpages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=&searchTab=searchByKey&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keywordSearch=Submit&searchType=inn&taxonomyPath=&treeNumber=&searchGenericType=generics&keyword=Lenalidomide" class="external text external">by INN</a></span></li>
<li><small><abbr class="country-name">US</abbr></small><span>&nbsp;</span>DailyMed:<span>&nbsp;</span><span><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lenalidomide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lenalidomide'" tppabs="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lenalidomide" class="external text external">Lenalidomide</a></span></li></ul></div>
</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Pregnancy<br>category</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>X (High risk)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-0"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>N (Not classified yet)<span> </span><span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-1"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span></li></ul>

<ul></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Routes of<br>administration</th><td>By mouth (capsules)</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ATC code</th><td><div class="plainlist"><ul><li>L04AX04<span> </span>(<span><a href="javascript:if(confirm('https://www.whocc.no/atc_ddd_index/?code=L04AX04  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.whocc.no/atc_ddd_index/?code=L04AX04'" tppabs="https://www.whocc.no/atc_ddd_index/?code=L04AX04" class="external text external">WHO</a></span>)<span> </span></li></ul></div></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Legal status</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Legal status</th><td><div class="plainlist">
<ul><li><small><abbr class="country-name">AU</abbr>:</small><span> </span>S4 (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">UK</abbr>:</small><span> </span>POM (Prescription only)<span> </span></li>
<li><small><abbr class="country-name">US</abbr>:</small><span> </span>℞-only<span> </span></li></ul></div>
</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Pharmacokinetic data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Bioavailability</th><td>Undetermined</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Protein binding</th><td>30%</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Metabolism</th><td>Undetermined</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Elimination <span class="nowrap">half-life</span></th><td>3 hours</td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Excretion</th><td>Kidney (67% unchanged)</td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Identifiers</th></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">IUPAC name</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; text-align:left; padding-left:1.5em; text-indent:-1.5em; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><span style="font-size: 11px;">(<i>RS</i>)-3-(4-Amino-1-oxo-1,3-dihydro-2<i>H</i>-isoindol-2-yl)piperidine-2,6-dione</span></li></ul>
</div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CAS Number</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.commonchemistry.org/ChemicalDetail.aspx?ref=191732-72-6  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.commonchemistry.org/ChemicalDetail.aspx?ref=191732-72-6'" tppabs="http://www.commonchemistry.org/ChemicalDetail.aspx?ref=191732-72-6" class="external text external">191732-72-6</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">PubChem <span style="font-weight:normal"><abbr>CID</abbr></span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://pubchem.ncbi.nlm.nih.gov/compound/216326  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubchem.ncbi.nlm.nih.gov/compound/216326'" tppabs="https://pubchem.ncbi.nlm.nih.gov/compound/216326" class="external text external">216326</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">IUPHAR/BPS</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7331  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7331'" tppabs="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7331" class="external text external">7331</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">DrugBank</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.drugbank.ca/drugs/DB00480  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugbank.ca/drugs/DB00480'" tppabs="https://www.drugbank.ca/drugs/DB00480" class="external text external">DB00480</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChemSpider</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('http://www.chemspider.com/Chemical-Structure.187515.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.chemspider.com/Chemical-Structure.187515.html'" tppabs="http://www.chemspider.com/Chemical-Structure.187515.html" class="external text external">187515</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">UNII</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=F0P408N6V4  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=F0P408N6V4'" tppabs="https://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=F0P408N6V4" class="external text external">F0P408N6V4</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">KEGG</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.kegg.jp/entry/D04687  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.kegg.jp/entry/D04687'" tppabs="https://www.kegg.jp/entry/D04687" class="external text external">D04687</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">ChEMBL</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL848  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL848'" tppabs="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/ChEMBL848" class="external text external">ChEMBL848</a></span><sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">CompTox Dashboard <span style="font-weight:normal">(<abbr>EPA</abbr>)</span></th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://comptox.epa.gov/dashboard/DTXSID8046664  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://comptox.epa.gov/dashboard/DTXSID8046664'" tppabs="https://comptox.epa.gov/dashboard/DTXSID8046664" class="external text external">DTXSID8046664</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;"><span>ECHA InfoCard</span></th><td><a href="javascript:if(confirm('https://echa.europa.eu/substance-information/-/substanceinfo/100.218.924  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://echa.europa.eu/substance-information/-/substanceinfo/100.218.924'" tppabs="https://echa.europa.eu/substance-information/-/substanceinfo/100.218.924" class="external text external">100.218.924</a> <figure-inline class="mw-valign-text-top"><img src="../I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/OOjs_UI_icon_edit-ltr-progressive.svg.png" data-file-width="20" data-file-height="20" data-file-type="drawing" height="10" width="10"></figure-inline></td></tr><tr><th colspan="2" style="text-align:center;background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Formula</th><td><span>C</span><sub>13</sub><span>H</span><sub>13</sub><span>N</span><sub>3</sub><span>O</span><sub>3</sub></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Molar mass</th><td><span class="nowrap">259.265</span><span>&nbsp;</span>g·mol<sup>−1</sup></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">3D model (JSmol)</th><td><div class="plainlist"><ul><li><span><a href="javascript:if(confirm('https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC1NC%28%3DO%29CCC1N3C%28%3DO%29c2cccc%28c2C3%29N  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC1NC%28%3DO%29CCC1N3C%28%3DO%29c2cccc%28c2C3%29N'" tppabs="https://chemapps.stolaf.edu/jmol/jmol.php?model=O%3DC1NC%28%3DO%29CCC1N3C%28%3DO%29c2cccc%28c2C3%29N" class="external text external">Interactive image</a></span></li></ul></div></td></tr><tr><th scope="row" style="padding:0.2em 0; line-height:1.2em;">Chirality</th><td>Racemic mixture</td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">SMILES</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">O=C1NC(=O)CCC1N3C(=O)c2cccc(c2C3)N</div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><div class="NavFrame collapsed" style="border: none; padding: 0;">
<div class="NavHead" style="font-size: 105%; background: transparent; text-align: left;">InChI</div>
<ul class="NavContent" style="list-style: none none; margin-left: 0; word-break:break-all; font-size: 105%; margin-top: 0; margin-bottom: 0; line-height: inherit;"><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li><li style="line-height: inherit; margin: 0"><div style="word-wrap:break-word; text-indent:-1.5em; text-align:left; padding-left:1.5em; font-size:11px; line-height:120%;">Key:GOTYRUGSSMKFNF-UHFFFAOYSA-N<sup><span>&nbsp;</span><figure-inline><span><img src="../I/m/Yes_check.svg.png" tppabs="https://ptable.com/wiki/compounds/I/m/Yes_check.svg.png" data-file-width="600" data-file-height="600" data-file-type="drawing" height="7" width="7"></span></figure-inline><span style="display:none">Y</span></sup></div></li></ul>
</div></td></tr><tr><td colspan="2" style="text-align:center"><style data-mw-deduplicate="TemplateStyles:r886047488">.mw-parser-output .nobold{font-weight:normal}</style><span class="nobold"><span>&nbsp;</span><span>&nbsp;</span><span class="reflink  nourlexpansion"><a href="javascript:if(confirm('https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459429828&page2=Lenalidomide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459429828&page2=Lenalidomide'" tppabs="https://en.wikipedia.org/w/index.php?title=Special:ComparePages&rev1=459429828&page2=Lenalidomide" class="external text external">(verify)</a></span></span></td></tr></tbody></table>

<p>Common side effects include diarrhea, itchiness, joint pain, fever, headache, and trouble sleeping.<span class="mw-ref" id="cite_ref-AHFS2019_2-3"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Severe side effects may include low blood platelets, low white blood cells, and blood clots.<span class="mw-ref" id="cite_ref-AHFS2019_2-4"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> Use during pregnancy may harm the baby.<span class="mw-ref" id="cite_ref-AHFS2019_2-5"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> The dose may need to be adjusted in people with kidney problems.<span class="mw-ref" id="cite_ref-AHFS2019_2-6"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It has a chemical structure similar to <a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">thalidomide</a> but has a different mechanism of action.<span class="mw-ref" id="cite_ref-PI2019_3-0"><a href="#cite_note-PI2019-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-AHFS2019_2-7"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> How it works is not entirely clear as of 2019.<span class="mw-ref" id="cite_ref-AHFS2019_2-8"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


<p>Lenalidomide was approved for medical use in the United States in 2005.<span class="mw-ref" id="cite_ref-AHFS2019_2-9"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span> It is on the World Health Organization's List of Essential Medicines.<span class="mw-ref" id="cite_ref-WHO21st_4-0"><a href="#cite_note-WHO21st-4" style="counter-reset: mw-Ref 4;"><span class="mw-reflink-text">[4]</span></a></span></p>


</div><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Medical_uses">Medical uses</h2></summary>
    


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Multiple_myeloma">Multiple myeloma</h3></summary>
    
<p>Lenalidomide is used to treat multiple myeloma.<span class="mw-ref" id="cite_ref-5"><a href="#cite_note-5" style="counter-reset: mw-Ref 5;"><span class="mw-reflink-text">[5]</span></a></span> It is a more potent molecular analog of thalidomide, which inhibits tumor angiogenesis, tumor-secreted cytokines, and tumor proliferation through induction of apoptosis.<span class="mw-ref" id="cite_ref-pmid20689431_6-0"><a href="#cite_note-pmid20689431-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span><span class="mw-ref" id="cite_ref-7"><a href="#cite_note-7" style="counter-reset: mw-Ref 7;"><span class="mw-reflink-text">[7]</span></a></span><span class="mw-ref" id="cite_ref-8"><a href="#cite_note-8" style="counter-reset: mw-Ref 8;"><span class="mw-reflink-text">[8]</span></a></span></p>

<p>Lenalidomide is effective at inducing a complete or "very good partial" response and improves progression-free survival. Adverse events more common in people receiving lenalidomide for myeloma include neutropenia, deep vein thrombosis, infections, and an increased risk of other hematological malignancies.<span class="mw-ref" id="cite_ref-9"><a href="#cite_note-9" style="counter-reset: mw-Ref 9;"><span class="mw-reflink-text">[9]</span></a></span> The risk of second primary hematological malignancies does not outweigh the benefit of using lenalidomide in relapsed or refractory multiple myeloma.<span class="mw-ref" id="cite_ref-10"><a href="#cite_note-10" style="counter-reset: mw-Ref 10;"><span class="mw-reflink-text">[10]</span></a></span> It may be more difficult to mobilize stem cells for autograft in people who have received lenalidomide.<span class="mw-ref" id="cite_ref-pmid20689431_6-1"><a href="#cite_note-pmid20689431-6" style="counter-reset: mw-Ref 6;"><span class="mw-reflink-text">[6]</span></a></span></p>

<p>In 2006, lenalidomide received U.S. Food and Drug Administration (FDA) clearance for use in combination with <a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">dexamethasone</a> in people with multiple myeloma who have received at least one prior therapy.<span class="mw-ref" id="cite_ref-11"><a href="#cite_note-11" style="counter-reset: mw-Ref 11;"><span class="mw-reflink-text">[11]</span></a></span> In 2017, the FDA approved lenalidomide as standalone maintenance therapy (without dexamethasone) for people with multiple myeloma following autologous stem cell transplant.<span class="mw-ref" id="cite_ref-12"><a href="#cite_note-12" style="counter-reset: mw-Ref 12;"><span class="mw-reflink-text">[12]</span></a></span></p>

<p>In 2009, The National Institute for Health and Clinical Excellence issued a final appraisal determination approving lenalidomide in combination with dexamethasone as an option to treat people with multiple myeloma who have received two or more prior therapies in England and Wales.<span class="mw-ref" id="cite_ref-13"><a href="#cite_note-13" style="counter-reset: mw-Ref 13;"><span class="mw-reflink-text">[13]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Myelodysplastic_syndromes">Myelodysplastic syndromes</h3></summary>
    
<p>Lenalidomide was approved by the FDA on 27 December 2005 for patients with low- or intermediate-1-risk myelodysplastic syndromes who have chromosome 5q deletion syndrome (5q- syndrome) with or without additional cytogenetic abnormalities.<span class="mw-ref" id="cite_ref-List_14-0"><a href="#cite_note-List-14" style="counter-reset: mw-Ref 14;"><span class="mw-reflink-text">[14]</span></a></span><span class="mw-ref" id="cite_ref-15"><a href="#cite_note-15" style="counter-reset: mw-Ref 15;"><span class="mw-reflink-text">[15]</span></a></span><span class="mw-ref" id="cite_ref-16"><a href="#cite_note-16" style="counter-reset: mw-Ref 16;"><span class="mw-reflink-text">[16]</span></a></span> It was approved on 17 June 2013 by the European Medicines Agency for use in patients with low- or intermediate-1-risk myelodysplastic syndromes who have 5q- deletion syndrome but no other cytogenetic abnormalities and are dependent on red blood cell transfusions, for whom other treatment options have been found to be insufficient or inadequate.<span class="mw-ref" id="cite_ref-17"><a href="#cite_note-17" style="counter-reset: mw-Ref 17;"><span class="mw-reflink-text">[17]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Mantle_cell_lymphoma">Mantle cell lymphoma</h3></summary>
    
<p>Lenalidomide is approved by FDA as a specialty drug requiring a specialty pharmacy distribution for mantle cell lymphoma in patients whose disease has relapsed or progressed after at least two prior therapies, one of which must have included <a href="Bortezomib.htm" tppabs="https://ptable.com/wiki/compounds/A/Bortezomib" title="Bortezomib">bortezomib</a>.<span class="mw-ref" id="cite_ref-PI2019_3-1"><a href="#cite_note-PI2019-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Adverse_effects">Adverse effects</h2></summary>
    

<p>In addition to embryo-fetal toxicity, lenalidomide carries black box warnings for hematologic toxicity (including neutropenia and thrombocytopenia) and thromboembolism.<span class="mw-ref" id="cite_ref-PI2019_3-2"><a href="#cite_note-PI2019-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span> Serious potential side effects include thrombosis, pulmonary embolus, hepatotoxicity, and bone marrow toxicity resulting in neutropenia and thrombocytopenia. Myelosuppression is the major dose-limiting toxicity, which is not the case with thalidomide.<span class="mw-ref" id="cite_ref-18"><a href="#cite_note-18" style="counter-reset: mw-Ref 18;"><span class="mw-reflink-text">[18]</span></a></span></p>

<p>Lenalidomide may be associated with such adverse effects as second primary malignancy, severe cutaneous reactions, hypersensitivity reactions, tumor lysis syndrome, tumor flare reaction, hypothyroidism, and hyperthyroidism.<span class="mw-ref" id="cite_ref-PI2019_3-3"><a href="#cite_note-PI2019-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Teratogenicity">Teratogenicity</h3></summary>
    
<p>Lenalidomide is related to <a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">thalidomide</a>, which is known to be teratogenic. Tests in monkeys suggest that lenalidomide is likewise teratogenic.<span class="mw-ref" id="cite_ref-19"><a href="#cite_note-19" style="counter-reset: mw-Ref 19;"><span class="mw-reflink-text">[19]</span></a></span> It cannot be prescribed for women who are pregnant or who may become pregnant during therapy.<span class="mw-ref" id="cite_ref-Drugs.com_pregnancy_1-2"><a href="#cite_note-Drugs.com_pregnancy-1" style="counter-reset: mw-Ref 1;"><span class="mw-reflink-text">[1]</span></a></span> For this reason, the drug is only available in the United States through a restricted distribution system in conjunction with a risk evaluation and mitigation strategy. Females who may become pregnant must use at least two forms of reliable contraception during treatment and for at least four weeks after discontinuing treatment with lenalidomide.<span class="mw-ref" id="cite_ref-PI2019_3-4"><a href="#cite_note-PI2019-3" style="counter-reset: mw-Ref 3;"><span class="mw-reflink-text">[3]</span></a></span><span class="mw-ref" id="cite_ref-pharmacytimes_2014_20-0"><a href="#cite_note-pharmacytimes_2014-20" style="counter-reset: mw-Ref 20;"><span class="mw-reflink-text">[20]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Venous_thromboembolism">Venous thromboembolism</h3></summary>
    
<p>Lenalidomide, like its parent compound thalidomide, may cause venous thromboembolism (VTE), a potentially serious complication with their use. High rates of VTE have been found in patients with multiple myeloma who received thalidomide or lenalidomide in conjunction with <a href="Dexamethasone.htm" tppabs="https://ptable.com/wiki/compounds/A/Dexamethasone" title="Dexamethasone">dexamethasone</a>, <a href="Melphalan.htm" tppabs="https://ptable.com/wiki/compounds/A/Melphalan" title="Melphalan">melphalan</a>, or <a href="Doxorubicin.htm" tppabs="https://ptable.com/wiki/compounds/A/Doxorubicin" title="Doxorubicin">doxorubicin</a>.<span class="mw-ref" id="cite_ref-21"><a href="#cite_note-21" style="counter-reset: mw-Ref 21;"><span class="mw-reflink-text">[21]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="Stevens-Johnson_syndrome">Stevens-Johnson syndrome</h3></summary>
    

<p>In March 2008, the U.S. Food and Drug Administration (FDA) included lenalidomide on a list of twenty prescription drugs under investigation for potential safety problems. The drug was investigated for possibly increasing the risk of developing Stevens–Johnson syndrome, a life-threatening skin condition.<span class="mw-ref" id="cite_ref-22"><a href="#cite_note-22" style="counter-reset: mw-Ref 22;"><span class="mw-reflink-text">[22]</span></a></span></p>


</details>
<details data-level="3" open="">
    <summary class="section-heading"><h3 id="FDA_ongoing_safety_review">FDA ongoing safety review</h3></summary>
    

<p>In 2011, the FDA initiated an ongoing review of clinical trials that found an increased risk of developing cancers such as acute myelogenous leukemia and B-cell lymphoma,<span class="mw-ref" id="cite_ref-Badros_23-0"><a href="#cite_note-Badros-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> though it did not advise patients to discontinue treatment with lenalidomide.<span class="mw-ref" id="cite_ref-24"><a href="#cite_note-24" style="counter-reset: mw-Ref 24;"><span class="mw-reflink-text">[24]</span></a></span></p>


</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Mechanism_of_action">Mechanism of action</h2></summary>
    
<p>Lenalidomide has been used to successfully treat both inflammatory disorders and cancers in the past ten years. There are multiple mechanisms of action, and they can be simplified by organizing them as mechanisms of action <i>in vitro</i> and <i>in vivo</i>.<span class="mw-ref" id="cite_ref-25"><a href="#cite_note-25" style="counter-reset: mw-Ref 25;"><span class="mw-reflink-text">[25]</span></a></span> <i>In vitro</i>, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulation. <i>In vivo</i>, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. Lenalidomide has a broad range of activities that can be exploited to treat many hematologic and solid cancers.</p>

<p>On a molecular level, lenalidomide has been shown to interact with the ubiquitin E3 ligase cereblon<span class="mw-ref" id="cite_ref-26"><a href="#cite_note-26" style="counter-reset: mw-Ref 26;"><span class="mw-reflink-text">[26]</span></a></span> and target this enzyme to degrade the Ikaros transcription factors IKZF1 and IKZF3.<span class="mw-ref" id="cite_ref-27"><a href="#cite_note-27" style="counter-reset: mw-Ref 27;"><span class="mw-reflink-text">[27]</span></a></span> This mechanism was unexpected as it suggests that the major action of lenalidomide is to re-target the activity of an enzyme rather than block the activity of an enzyme or signaling process, and thereby represents a novel mode of drug action. A more specific implication of this mechanism is that the teratogenic and anti-neoplastic properties of lenalidomide, and perhaps other thalidomide derivatives, could be disassociated.</p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="History">History</h2></summary>
    

<p>Lenalidomide was approved for medical use in the United States in 2005.<span class="mw-ref" id="cite_ref-AHFS2019_2-10"><a href="#cite_note-AHFS2019-2" style="counter-reset: mw-Ref 2;"><span class="mw-reflink-text">[2]</span></a></span></p>


    <details data-level="3" open="">
    <summary class="section-heading"><h3 id="Society_and_culture">Society and culture</h3></summary>
    

</details>

</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Economics">Economics</h2></summary>
    
<p>Lenalidomide costs <span style="white-space: nowrap">US$163,381</span> per year for the average person in the United States as of 2012.<span class="mw-ref" id="cite_ref-Badros_23-1"><a href="#cite_note-Badros-23" style="counter-reset: mw-Ref 23;"><span class="mw-reflink-text">[23]</span></a></span> Lenalidomide made almost $9.7bn for Celgene in 2018.<span class="mw-ref" id="cite_ref-genengnews_2019_28-0"><a href="#cite_note-genengnews_2019-28" style="counter-reset: mw-Ref 28;"><span class="mw-reflink-text">[28]</span></a></span></p>

<p>In 2013, the UK National Institute for Health and Care Excellence (NICE) rejected lenalidomide for "use in the treatment of people with a specific type of the bone marrow disorder myelodysplastic syndrome (MDS)" in England and Scotland, arguing that Celgene "did not provide enough evidence to justify the <span style="white-space: nowrap">GB£3,780</span> per month (<span style="white-space: nowrap">US$5,746.73</span>) price-tag of lenalidomide for use in the treatment of people with a specific type of the bone marrow disorder myelodysplastic syndrome (MDS)".<span class="mw-ref" id="cite_ref-pmlive.com_29-0"><a href="#cite_note-pmlive.com-29" style="counter-reset: mw-Ref 29;"><span class="mw-reflink-text">[29]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="Research">Research</h2></summary>
    
<p>Lenalidomide is undergoing clinical trial as a treatment for Hodgkin's lymphoma,<span class="mw-ref" id="cite_ref-30"><a href="#cite_note-30" style="counter-reset: mw-Ref 30;"><span class="mw-reflink-text">[30]</span></a></span> as well as non-Hodgkin's lymphoma, chronic lymphocytic leukemia and solid tumor cancers, such as carcinoma of the pancreas.<span class="mw-ref" id="cite_ref-31"><a href="#cite_note-31" style="counter-reset: mw-Ref 31;"><span class="mw-reflink-text">[31]</span></a></span> One Phase III clinical trial being conducted by Celgene in elderly patients with B-cell chronic lymphocytic leukemia was halted in July 2013, when a disproportionate number of cancer deaths were observed during treatment with lenalidomide versus patients treated with <a href="Chlorambucil.htm" tppabs="https://ptable.com/wiki/compounds/A/Chlorambucil" title="Chlorambucil">chlorambucil</a>.<span class="mw-ref" id="cite_ref-32"><a href="#cite_note-32" style="counter-reset: mw-Ref 32;"><span class="mw-reflink-text">[32]</span></a></span></p>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="References">References</h2></summary>
    
<div class="reflist " style=" list-style-type: decimal;">
<div class="mw-references-wrap mw-references-columns"><ol class="mw-references references"><li id="cite_note-Drugs.com_pregnancy-1"> <span id="mw-reference-text-cite_note-Drugs.com_pregnancy-1" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/pregnancy/lenalidomide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/pregnancy/lenalidomide.html'" tppabs="https://www.drugs.com/pregnancy/lenalidomide.html" class="external text external">"Lenalidomide (Revlimid) Use During Pregnancy"</a>. <i>Drugs.com</i>. 13 March 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">13 August</span> 2020</span>.</cite></span></li><li id="cite_note-AHFS2019-2"> <span id="mw-reference-text-cite_note-AHFS2019-2" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.drugs.com/monograph/lenalidomide.html  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.drugs.com/monograph/lenalidomide.html'" tppabs="https://www.drugs.com/monograph/lenalidomide.html" class="external text external">"Lenalidomide Monograph for Professionals"</a>. <i>Drugs.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">27 October</span> 2019</span>.</cite></span></li><li id="cite_note-PI2019-3"> <span id="mw-reference-text-cite_note-PI2019-3" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be'" tppabs="https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be" class="external text external">"DailyMed - Revlimid- lenalidomide capsule"</a>. <i>dailymed.nlm.nih.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">27 October</span> 2019</span>.</cite></span></li><li id="cite_note-WHO21st-4"> <span id="mw-reference-text-cite_note-WHO21st-4" class="mw-reference-text"><cite id="CITEREFWorld_Health_Organization2019" class="citation book cs1">World Health Organization (2019). <i>World Health Organization model list of essential medicines: 21st list 2019</i>. Geneva: World Health Organization. hdl:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://hdl.handle.net/10665%2F325771  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://hdl.handle.net/10665%2F325771'" tppabs="https://hdl.handle.net/10665%2F325771" class="external text external">10665/325771</a></span>. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.</cite></span></li><li id="cite_note-5"> <span id="mw-reference-text-cite_note-5" class="mw-reference-text"><cite id="CITEREFArmoiryAulagnerFacon2008" class="citation journal cs1">Armoiry X, Aulagner G, Facon T (June 2008). "Lenalidomide in the treatment of multiple myeloma: a review". <i>Journal of Clinical Pharmacy and Therapeutics</i>. <b>33</b> (3): 219–26. doi:<a href="javascript:if(confirm('https://doi.org/10.1111%2Fj.1365-2710.2008.00920.x  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1111%2Fj.1365-2710.2008.00920.x'" tppabs="https://doi.org/10.1111%2Fj.1365-2710.2008.00920.x" class="external text external">10.1111/j.1365-2710.2008.00920.x</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18452408  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18452408'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18452408" class="external text external">18452408</a>.</cite></span></li><li id="cite_note-pmid20689431-6"> <span id="mw-reference-text-cite_note-pmid20689431-6" class="mw-reference-text"><cite id="CITEREFLiGillLentzsch2010" class="citation journal cs1">Li S, Gill N, Lentzsch S (November 2010). "Recent advances of IMiDs in cancer therapy". <i>Curr Opin Oncol</i>. <b>22</b> (6): 579–85. doi:<a href="javascript:if(confirm('https://doi.org/10.1097%2FCCO.0b013e32833d752c  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1097%2FCCO.0b013e32833d752c'" tppabs="https://doi.org/10.1097%2FCCO.0b013e32833d752c" class="external text external">10.1097/CCO.0b013e32833d752c</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/20689431  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/20689431'" tppabs="https://pubmed.ncbi.nlm.nih.gov/20689431" class="external text external">20689431</a>.</cite></span></li><li id="cite_note-7"> <span id="mw-reference-text-cite_note-7" class="mw-reference-text"><cite id="CITEREFTageja2011" class="citation journal cs1">Tageja N (March 2011). "Lenalidomide - current understanding of mechanistic properties". <i>Anti-Cancer Agents Med. Chem</i>. <b>11</b> (3): 315–26. doi:<a href="javascript:if(confirm('https://doi.org/10.2174%2F187152011795347487  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2174%2F187152011795347487'" tppabs="https://doi.org/10.2174%2F187152011795347487" class="external text external">10.2174/187152011795347487</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21426296  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21426296'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21426296" class="external text external">21426296</a>.</cite></span></li><li id="cite_note-8"> <span id="mw-reference-text-cite_note-8" class="mw-reference-text"><cite id="CITEREFKotlaGoelNischalHeuck2009" class="citation journal cs1">Kotla V, Goel S, Nischal S,  et al. (August 2009). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171" class="external text external">"Mechanism of action of lenalidomide in hematological malignancies"</a>. <i>J Hematol Oncol</i>. <b>2</b>: 36. doi:<a href="javascript:if(confirm('https://doi.org/10.1186%2F1756-8722-2-36  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1186%2F1756-8722-2-36'" tppabs="https://doi.org/10.1186%2F1756-8722-2-36" class="external text external">10.1186/1756-8722-2-36</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736171" class="external text external">2736171</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/19674465  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/19674465'" tppabs="https://pubmed.ncbi.nlm.nih.gov/19674465" class="external text external">19674465</a>.</cite></span></li><li id="cite_note-9"> <span id="mw-reference-text-cite_note-9" class="mw-reference-text"><cite id="CITEREFYangYuChiLu2013" class="citation journal cs1">Yang B, Yu RL, Chi XH,  et al. (2013). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653900  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653900'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653900" class="external text external">"Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials"</a>. <i>PLoS ONE</i>. <b>8</b> (5): e64354. Bibcode:<a href="javascript:if(confirm('https://ui.adsabs.harvard.edu/abs/2013PLoSO...864354Y  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://ui.adsabs.harvard.edu/abs/2013PLoSO...864354Y'" tppabs="https://ui.adsabs.harvard.edu/abs/2013PLoSO...864354Y" class="external text external">2013PLoSO...864354Y</a>. doi:<a href="javascript:if(confirm('https://doi.org/10.1371%2Fjournal.pone.0064354  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1371%2Fjournal.pone.0064354'" tppabs="https://doi.org/10.1371%2Fjournal.pone.0064354" class="external text external">10.1371/journal.pone.0064354</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653900  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653900'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653900" class="external text external">3653900</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/23691202  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/23691202'" tppabs="https://pubmed.ncbi.nlm.nih.gov/23691202" class="external text external">23691202</a>.</cite></span></li><li id="cite_note-10"> <span id="mw-reference-text-cite_note-10" class="mw-reference-text"><cite id="CITEREFDimopoulosRichardsonBrandenburgYu2012" class="citation journal cs1">Dimopoulos MA, Richardson PG, Brandenburg N,  et al. (22 March 2012). <a href="javascript:if(confirm('https://doi.org/10.1182/blood-2011-08-373514  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182/blood-2011-08-373514'" tppabs="https://doi.org/10.1182/blood-2011-08-373514" class="external text external">"A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide"</a>. <i>Blood</i>. <b>119</b> (12): 2764–7. doi:<span class="cs1-lock-free"><a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood-2011-08-373514  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood-2011-08-373514'" tppabs="https://doi.org/10.1182%2Fblood-2011-08-373514" class="external text external">10.1182/blood-2011-08-373514</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22323483  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22323483'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22323483" class="external text external">22323483</a>.</cite></span></li><li id="cite_note-11"> <span id="mw-reference-text-cite_note-11" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm'" tppabs="https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095626.htm" class="external text external">"FDA approves lenalidomide oral capsules (Revlimid) for use in combination with dexamethasone in patients with multiple myeloma"</a>. Food and Drug Administration (FDA). 29 June 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2015</span>.</cite></span></li><li id="cite_note-12"> <span id="mw-reference-text-cite_note-12" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid'" tppabs="https://www.fda.gov/drugs/resources-information-approved-drugs/lenalidomide-revlimid" class="external text external">"Lenalidomide (Revlimid)"</a>. Food and Drug Administration (FDA). 22 February 2017.</cite></span></li><li id="cite_note-13"> <span id="mw-reference-text-cite_note-13" class="mw-reference-text"><cite class="citation news cs1"><a href="javascript:if(confirm('https://www.reuters.com/article/pressRelease/idUS83290+23-Apr-2009+BW20090423  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.reuters.com/article/pressRelease/idUS83290+23-Apr-2009+BW20090423'" tppabs="https://www.reuters.com/article/pressRelease/idUS83290+23-Apr-2009+BW20090423" class="external text external">"REVLIMID Receives Positive Final Appraisal Determination from National Institute for Health and Clinical Excellence (NICE) for Use in the National Health Service (NHS) in England and Wales"</a>. <i>Reuters</i>. 23 April 2009.</cite></span></li><li id="cite_note-List-14"> <span id="mw-reference-text-cite_note-List-14" class="mw-reference-text"><cite id="CITEREFListKurtinRoe2005" class="citation journal cs1">List A, Kurtin S, Roe DJ,  et al. (February 2005). "Efficacy of lenalidomide in myelodysplastic syndromes". <i>The New England Journal of Medicine</i>. <b>352</b> (6): 549–57. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa041668  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa041668'" tppabs="https://doi.org/10.1056%2FNEJMoa041668" class="external text external">10.1056/NEJMoa041668</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/15703420  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/15703420'" tppabs="https://pubmed.ncbi.nlm.nih.gov/15703420" class="external text external">15703420</a>.</cite></span></li><li id="cite_note-15"> <span id="mw-reference-text-cite_note-15" class="mw-reference-text"><cite id="CITEREFList2005" class="citation journal cs1">List AF (August 2005). "Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS)". <i>Seminars in Oncology</i>. <b>32</b> (4 Suppl 5): S31–5. doi:<a href="javascript:if(confirm('https://doi.org/10.1053%2Fj.seminoncol.2005.06.020  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1053%2Fj.seminoncol.2005.06.020'" tppabs="https://doi.org/10.1053%2Fj.seminoncol.2005.06.020" class="external text external">10.1053/j.seminoncol.2005.06.020</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/16085015  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/16085015'" tppabs="https://pubmed.ncbi.nlm.nih.gov/16085015" class="external text external">16085015</a>.</cite></span></li><li id="cite_note-16"> <span id="mw-reference-text-cite_note-16" class="mw-reference-text"><cite id="CITEREFListDewaldBennettGiagounidis2006" class="citation journal cs1">List A, Dewald G, Bennett J,  et al. (October 2006). "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion". <i>The New England Journal of Medicine</i>. <b>355</b> (14): 1456–65. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMoa061292  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMoa061292'" tppabs="https://doi.org/10.1056%2FNEJMoa061292" class="external text external">10.1056/NEJMoa061292</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17021321  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17021321'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17021321" class="external text external">17021321</a>.</cite></span></li><li id="cite_note-17"> <span id="mw-reference-text-cite_note-17" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.mdsbeacon.com/news/2013/06/17/revlimid-lenalidomide-european-approval-mds/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.mdsbeacon.com/news/2013/06/17/revlimid-lenalidomide-european-approval-mds/'" tppabs="http://www.mdsbeacon.com/news/2013/06/17/revlimid-lenalidomide-european-approval-mds/" class="external text external">"Revlimid Approved In Europe For Use In Myelodysplastic Syndromes"</a>. The MDS Beacon<span class="reference-accessdate">. Retrieved <span class="nowrap">17 June</span> 2013</span>.</cite></span></li><li id="cite_note-18"> <span id="mw-reference-text-cite_note-18" class="mw-reference-text"><cite id="CITEREFRao2007" class="citation journal cs1">Rao KV (September 2007). "Lenalidomide in the treatment of multiple myeloma". <i>American Journal of Health-System Pharmacy</i>. <b>64</b> (17): 1799–807. doi:<a href="javascript:if(confirm('https://doi.org/10.2146%2Fajhp070029  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.2146%2Fajhp070029'" tppabs="https://doi.org/10.2146%2Fajhp070029" class="external text external">10.2146/ajhp070029</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17724360  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17724360'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17724360" class="external text external">17724360</a>.</cite></span></li><li id="cite_note-19"> <span id="mw-reference-text-cite_note-19" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf'" tppabs="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000717/WC500056018.pdf" class="external text external">"Revlimid Summary of Product Characteristics. Annex I"</a> <span class="cs1-format">(PDF)</span>. European Medicines Agency. 2012. p.<span>&nbsp;</span>6.</cite></span></li><li id="cite_note-pharmacytimes_2014-20"> <span id="mw-reference-text-cite_note-pharmacytimes_2014-20" class="mw-reference-text"><cite id="CITEREFNess2014" class="citation web cs1">Ness, Stacey (13 March 2014). <a href="javascript:if(confirm('http://www.pharmacytimes.com/publications/issue/2014/march2014/new-specialty-drugs  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pharmacytimes.com/publications/issue/2014/march2014/new-specialty-drugs'" tppabs="http://www.pharmacytimes.com/publications/issue/2014/march2014/new-specialty-drugs" class="external text external">"New Specialty Drugs"</a>. Pharmacy Times<span class="reference-accessdate">. Retrieved <span class="nowrap">5 November</span> 2015</span>.</cite></span></li><li id="cite_note-21"> <span id="mw-reference-text-cite_note-21" class="mw-reference-text"><cite id="CITEREFBennettAngelottaYarnold2006" class="citation journal cs1">Bennett CL, Angelotta C, Yarnold PR,  et al. (December 2006). "Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer". <i>JAMA: The Journal of the American Medical Association</i>. <b>296</b> (21): 2558–60. doi:<a href="javascript:if(confirm('https://doi.org/10.1001%2Fjama.296.21.2558-c  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1001%2Fjama.296.21.2558-c'" tppabs="https://doi.org/10.1001%2Fjama.296.21.2558-c" class="external text external">10.1001/jama.296.21.2558-c</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/17148721  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/17148721'" tppabs="https://pubmed.ncbi.nlm.nih.gov/17148721" class="external text external">17148721</a>.</cite></span></li><li id="cite_note-22"> <span id="mw-reference-text-cite_note-22" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm085914.htm  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm085914.htm'" tppabs="https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/ucm085914.htm" class="external text external">"Potential Signals of Serious Risks/New Safety Information Identified from the Adverse Event Reporting System (AERS) between January - March 2008"</a>. Food and Drug Administration (FDA). March 2008.</cite>
</span></li><li id="cite_note-Badros-23"> <span id="mw-reference-text-cite_note-Badros-23" class="mw-reference-text"><cite id="CITEREFBadros2012" class="citation journal cs1">Badros AZ (10 May 2012). "Lenalidomide in Myeloma — A High-Maintenance Friend". <i>N Engl J Med</i>. <b>366</b> (19): 1836–1838. doi:<a href="javascript:if(confirm('https://doi.org/10.1056%2FNEJMe1202819  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1056%2FNEJMe1202819'" tppabs="https://doi.org/10.1056%2FNEJMe1202819" class="external text external">10.1056/NEJMe1202819</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/22571206  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/22571206'" tppabs="https://pubmed.ncbi.nlm.nih.gov/22571206" class="external text external">22571206</a>.</cite></span></li><li id="cite_note-24"> <span id="mw-reference-text-cite_note-24" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-ongoing-safety-review-revlimid-lenalidomide-and-possible-increased  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-ongoing-safety-review-revlimid-lenalidomide-and-possible-increased'" tppabs="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-ongoing-safety-review-revlimid-lenalidomide-and-possible-increased" class="external text external">"FDA Drug Safety Communication: Ongoing safety review of Revlimid (lenalidomide) and possible increased risk of developing new malignancies"</a>. Food and Drug Administration (FDA). April 2011.</cite>
</span></li><li id="cite_note-25"> <span id="mw-reference-text-cite_note-25" class="mw-reference-text"><cite id="CITEREFValletPalumboRajeBoccadoro2008" class="citation journal cs1">Vallet S, Palumbo A, Raje N,  et al. (July 2008). "Thalidomide and lenalidomide: Mechanism-based potential drug combinations". <i>Leukemia &amp; Lymphoma</i>. <b>49</b> (7): 1238–45. doi:<a href="javascript:if(confirm('https://doi.org/10.1080%2F10428190802005191  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1080%2F10428190802005191'" tppabs="https://doi.org/10.1080%2F10428190802005191" class="external text external">10.1080/10428190802005191</a>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/18452080  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/18452080'" tppabs="https://pubmed.ncbi.nlm.nih.gov/18452080" class="external text external">18452080</a>.</cite></span></li><li id="cite_note-26"> <span id="mw-reference-text-cite_note-26" class="mw-reference-text"><cite id="CITEREFZhuBraggioShiBruins2011" class="citation journal cs1">Zhu YX, Braggio E, Shi CX,  et al. (2011). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291" class="external text external">"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide"</a>. <i>Blood</i>. <b>118</b> (18): 4771–9. doi:<a href="javascript:if(confirm('https://doi.org/10.1182%2Fblood-2011-05-356063  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1182%2Fblood-2011-05-356063'" tppabs="https://doi.org/10.1182%2Fblood-2011-05-356063" class="external text external">10.1182/blood-2011-05-356063</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3208291" class="external text external">3208291</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/21860026  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/21860026'" tppabs="https://pubmed.ncbi.nlm.nih.gov/21860026" class="external text external">21860026</a>.</cite></span></li><li id="cite_note-27"> <span id="mw-reference-text-cite_note-27" class="mw-reference-text"><cite id="CITEREFStewart2014" class="citation journal cs1">Stewart AK (2014). <a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783" class="external text external">"Medicine. How thalidomide works against cancer"</a>. <i>Science</i>. <b>343</b> (6168): 256–7. doi:<a href="javascript:if(confirm('https://doi.org/10.1126%2Fscience.1249543  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://doi.org/10.1126%2Fscience.1249543'" tppabs="https://doi.org/10.1126%2Fscience.1249543" class="external text external">10.1126/science.1249543</a>. PMC<span>&nbsp;</span><span class="cs1-lock-free"><a href="javascript:if(confirm('https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783'" tppabs="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4084783" class="external text external">4084783</a></span>. PMID<span>&nbsp;</span><a href="javascript:if(confirm('https://pubmed.ncbi.nlm.nih.gov/24436409  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://pubmed.ncbi.nlm.nih.gov/24436409'" tppabs="https://pubmed.ncbi.nlm.nih.gov/24436409" class="external text external">24436409</a>.</cite></span></li><li id="cite_note-genengnews_2019-28"> <span id="mw-reference-text-cite_note-genengnews_2019-28" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('https://www.genengnews.com/a-lists/top-10-best-selling-cancer-drugs-of-2018/  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://www.genengnews.com/a-lists/top-10-best-selling-cancer-drugs-of-2018/'" tppabs="https://www.genengnews.com/a-lists/top-10-best-selling-cancer-drugs-of-2018/" class="external text external">"Top 10 Best-Selling Cancer Drugs of 2018"</a>. Genetic Engineering and Biotechnology News. 22 April 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">25 April</span> 2019</span>.</cite></span></li><li id="cite_note-pmlive.com-29"> <span id="mw-reference-text-cite_note-pmlive.com-29" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.pmlive.com/pharma_news/revlimid_faces_nice_rejection_for_use_in_rare_blood_cancer_488554  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.pmlive.com/pharma_news/revlimid_faces_nice_rejection_for_use_in_rare_blood_cancer_488554'" tppabs="http://www.pmlive.com/pharma_news/revlimid_faces_nice_rejection_for_use_in_rare_blood_cancer_488554" class="external text external">"Revlimid faces NICE rejection for use in rare blood cancer Watchdog's draft guidance does not recommend Celgene's drug for NHS use in England and Wales"</a>. Pharma News. 11 July 2013<span class="reference-accessdate">. Retrieved <span class="nowrap">5 November</span> 2015</span>.</cite></span></li><li id="cite_note-30"> <span id="mw-reference-text-cite_note-30" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://clinicaltrials.gov/ct2/show/NCT00478959  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://clinicaltrials.gov/ct2/show/NCT00478959'" tppabs="http://clinicaltrials.gov/ct2/show/NCT00478959" class="external text external">"Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma"</a>. <i>ClinicalTrials.gov</i>. US National Institutes of Health. February 2009.</cite>
</span></li><li id="cite_note-31"> <span id="mw-reference-text-cite_note-31" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://clinicaltrials.gov/ct2/results?term=lenalidomide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://clinicaltrials.gov/ct2/results?term=lenalidomide'" tppabs="http://clinicaltrials.gov/ct2/results?term=lenalidomide" class="external text external">"276 current clinical trials world-wide, both recruiting and fully enrolled, as of 27 February 2009"</a>. <i>ClinicalTrials.gov</i>. US National Institutes of Health. February 2009.</cite></span></li><li id="cite_note-32"> <span id="mw-reference-text-cite_note-32" class="mw-reference-text"><cite class="citation web cs1"><a href="javascript:if(confirm('http://www.nasdaq.com/article/celgene-discontinues-phase-3-revlimid-study-after-imbalance-of-deaths-20130718-00399  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='http://www.nasdaq.com/article/celgene-discontinues-phase-3-revlimid-study-after-imbalance-of-deaths-20130718-00399'" tppabs="http://www.nasdaq.com/article/celgene-discontinues-phase-3-revlimid-study-after-imbalance-of-deaths-20130718-00399" class="external text external">"Celgene Discontinues Phase 3 Revlimid Study after 'Imbalance' of Deaths"</a>. Nasdaq. 18 July 2013.</cite></span></li></ol></div></div>


    
</details><details data-level="2" open="">
    <summary class="section-heading"><h2 id="External_links">External links</h2></summary>
    
<ul><li><cite class="citation web cs1"><a href="javascript:if(confirm('https://druginfo.nlm.nih.gov/drugportal/name/lenalidomide  \n\nThis file was not retrieved by Teleport VLX, because it is addressed on a domain or path outside the boundaries set for its Starting Address.  \n\nDo you want to open it from the server?'))window.location='https://druginfo.nlm.nih.gov/drugportal/name/lenalidomide'" tppabs="https://druginfo.nlm.nih.gov/drugportal/name/lenalidomide" class="external text external">"Lenalidomide"</a>. <i>Drug Information Portal</i>. U.S. National Library of Medicine.</cite></li></ul>

<div role="navigation" class="navbox" aria-labelledby="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><div id="Immunosuppressive_drugs_/_Immunosuppressants_(L04)" style="font-size:114%;margin:0 4em">Immunosuppressive drugs<span>&nbsp;</span>/ Immunosuppressants (L04)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(initiation)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Antimetabolites</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>purine synthesis inhibitors</i>
<ul><li><a href="Azathioprine.htm" tppabs="https://ptable.com/wiki/compounds/A/Azathioprine" title="Azathioprine">Azathioprine</a></li>
<li><a href="Mycophenolic_acid.htm" tppabs="https://ptable.com/wiki/compounds/A/Mycophenolic_acid" title="Mycophenolic acid">Mycophenolic acid</a></li></ul></li></ul>

<ul><li><i>pyrimidine synthesis inhibitors</i>
<ul><li><a href="Leflunomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Leflunomide" title="Leflunomide">Leflunomide</a></li>
<li>Teriflunomide</li></ul></li></ul>

<ul><li><i>antifolate</i>
<ul><li><a href="Methotrexate.htm" tppabs="https://ptable.com/wiki/compounds/A/Methotrexate" title="Methotrexate">Methotrexate</a></li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Macrolides/<br>other <a href="Interleukin_2.htm" tppabs="https://ptable.com/wiki/compounds/A/Interleukin_2" title="Interleukin 2">IL-2</a> inhibitors</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>FKBP/Cyclophilin/Calcineurin</i>
<ul><li><a href="Tacrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Tacrolimus" title="Tacrolimus">Tacrolimus</a></li>
<li><a href="Ciclosporin.htm" tppabs="https://ptable.com/wiki/compounds/A/Ciclosporin" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="Pimecrolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Pimecrolimus" title="Pimecrolimus">Pimecrolimus</a></li></ul></li></ul>

<ul><li>Abetimus</li>
<li>Gusperimus</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">IMiDs</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Lenalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Lenalidomide" title="Lenalidomide">Lenalidomide</a></li>
<li>Pomalidomide</li>
<li><a href="Thalidomide.htm" tppabs="https://ptable.com/wiki/compounds/A/Thalidomide" title="Thalidomide">Thalidomide</a></li>
<li><i>PDE4 inhibitor</i>
<ul><li>Apremilast</li></ul></li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Intracellular<br>(reception)</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">IL-1 receptor antagonists</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Anakinra.htm" tppabs="https://ptable.com/wiki/compounds/A/Anakinra" title="Anakinra">Anakinra</a></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">mTOR</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><a href="Sirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Sirolimus" title="Sirolimus">Sirolimus</a></li>
<li><a href="Everolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Everolimus" title="Everolimus">Everolimus</a></li>
<li>Ridaforolimus</li>
<li><a href="Temsirolimus.htm" tppabs="https://ptable.com/wiki/compounds/A/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li>
<li>Umirolimus</li>
<li>Zotarolimus</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Extracellular</th><td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="Antibody.htm" tppabs="https://ptable.com/wiki/compounds/A/Antibody" title="Antibody">Antibodies</a></th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Monoclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Serum target<br>(noncellular)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>Complement component 5</i>
<ul><li>Eculizumab</li></ul></li>
<li><i>TNF</i>
<ul><li><a href="Adalimumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Adalimumab" title="Adalimumab">Adalimumab</a></li>
<li>Afelimomab</li>
<li>Certolizumab pegol</li>
<li>Golimumab</li>
<li><a href="Infliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Infliximab" title="Infliximab">Infliximab</a></li>
<li>Nerelimomab</li></ul></li>
<li><i>Interleukin 5</i>
<ul><li>Mepolizumab</li></ul></li>
<li><i>Immunoglobulin E</i>
<ul><li><a href="Omalizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Omalizumab" title="Omalizumab">Omalizumab</a></li></ul></li></ul>

<ul><li><i>Interferon</i>
<ul><li>Faralimomab</li></ul></li></ul>

<ul><li><i>IL-6</i>
<ul><li>Elsilimomab</li></ul></li></ul>

<ul><li><i>IL-12 and IL-23</i>
<ul><li>Lebrikizumab</li>
<li>Ustekinumab</li></ul></li></ul>

<ul><li><i>IL-17A</i>
<ul><li>Secukinumab</li></ul></li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Cellular<br>target</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CD3</i>
<ul><li><a href="Muromonab-CD3.htm" tppabs="https://ptable.com/wiki/compounds/A/Muromonab-CD3" title="Muromonab-CD3">Muromonab-CD3</a></li>
<li>Otelixizumab</li>
<li>Teplizumab</li>
<li>Visilizumab</li></ul></li>
<li><i>CD4</i>
<ul><li>Clenoliximab</li>
<li>Keliximab</li>
<li>Zanolimumab</li></ul></li>
<li><i>CD11a</i>
<ul><li>Efalizumab</li></ul></li>
<li><i>CD18</i>
<ul><li>Erlizumab</li></ul></li>
<li><i>CD20</i>
<ul><li>Obinutuzumab</li>
<li><a href="Rituximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Rituximab" title="Rituximab">Rituximab</a></li>
<li>Ocrelizumab</li>
<li>Pascolizumab</li></ul></li>
<li><i>CD23</i>
<ul><li>Gomiliximab</li>
<li>Lumiliximab</li></ul></li>
<li><i>CD40</i>
<ul><li>Teneliximab</li>
<li>Toralizumab</li></ul></li>
<li><i>CD62L/L-selectin</i>
<ul><li>Aselizumab</li></ul></li>
<li><i>CD80</i>
<ul><li>Galiximab</li></ul></li>
<li><i>CD147/Basigin</i>
<ul><li>Gavilimomab</li></ul></li>
<li><i>CD154</i>
<ul><li>Ruplizumab</li></ul></li></ul>

<ul><li><i>BLyS</i>
<ul><li>Belimumab</li>
<li>Blisibimod</li></ul></li>
<li><i>CTLA-4</i>
<ul><li>Ipilimumab</li>
<li>Tremelimumab</li></ul></li>
<li><i>CAT</i>
<ul><li>Bertilimumab</li>
<li>Lerdelimumab</li>
<li>Metelimumab</li></ul></li>
<li><i>Integrin</i>
<ul><li>Natalizumab</li>
<li>Vedolizumab</li></ul></li>
<li><i>Interleukin-6 receptor</i>
<ul><li>Tocilizumab</li></ul></li>
<li><i>LFA-1</i>
<ul><li>Odulimomab</li></ul></li></ul>

<ul><li><i>IL-2 receptor/CD25</i>
<ul><li><a href="Basiliximab.htm" tppabs="https://ptable.com/wiki/compounds/A/Basiliximab" title="Basiliximab">Basiliximab</a></li>
<li><a href="Daclizumab.htm" tppabs="https://ptable.com/wiki/compounds/A/Daclizumab" title="Daclizumab">Daclizumab</a></li>
<li>Inolimomab</li></ul></li></ul>

<ul><li><i>T-lymphocyte</i> (Zolimomab aritox)</li></ul>
</div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Unsorted</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Atorolimumab</li>
<li>Cedelizumab</li>
<li>Fontolizumab</li>
<li>Maslimomab</li>
<li>Morolimumab</li>
<li>Pexelizumab</li>
<li>Reslizumab</li>
<li>Rovelizumab</li>
<li>Siplizumab</li>
<li>Talizumab</li>
<li>Telimomab aritox</li>
<li>Vapaliximab</li>
<li>Vepalimomab</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Polyclonal</th><td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li>Anti-thymocyte globulin</li>
<li>Anti-lymphocyte globulin</li></ul>
</div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">-cept (Fusion)</th><td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px"><div style="padding:0em 0.25em">
<ul><li><i>CTLA-4</i>
<ul><li>Abatacept</li>
<li>Belatacept</li></ul></li>
<li><i>TNF inhibitor</i>
<ul><li><a href="Etanercept.htm" tppabs="https://ptable.com/wiki/compounds/A/Etanercept" title="Etanercept">Etanercept</a></li>
<li>Pegsunercept</li></ul></li>
<li>Aflibercept</li>
<li><a href="Alefacept.htm" tppabs="https://ptable.com/wiki/compounds/A/Alefacept" title="Alefacept">Alefacept</a></li>
<li>Rilonacept</li></ul>
</div></td></tr></tbody></table><div></div></td></tr></tbody></table></div>









<style data-mw-deduplicate="TemplateStyles:r951705291">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg*/);background-repeat:no-repeat;background-size:9px;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background-image:url("../../../../upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png"/*tpa=https://upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png*/);background-image:linear-gradient(transparent,transparent),url("../../../../upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg"/*tpa=https://upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg*/);background-repeat:no-repeat;background-size:12px;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}</style>
    
</details></div>
        </div>
      </div>
    </div>
  </div>
  <script src="../-/j/js_modules/jsConfigVars.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jsConfigVars.js" class=""></script>
  <script src="../-/j/js_modules/startup.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/startup.js" class=""></script>
<script src="../-/j/js_modules/jquery.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/jquery.js" class=""></script>
<script src="../-/j/js_modules/mediawiki.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/mediawiki.js" class=""></script>
<script src="../-/j/js_modules/site.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/site.js" class=""></script>
<script src="../-/j/js_modules/ext.cite.ux-enhancements.js" tppabs="https://ptable.com/wiki/compounds/-/j/js_modules/ext.cite.ux-enhancements.js" class=""></script>



</body></html>